A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

V.A. Miller; Arabinda K. Das; M. Rossi

doi:10.1200/jco.2009.27.15_suppl.lba8002

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

V.A. Miller(Memorial Sloan Kettering Cancer Center), Arabinda K. Das(Memorial Sloan Kettering Cancer Center), M. Rossi(Memorial Sloan Kettering Cancer Center)

Journal of Clinical Oncology

May 20, 2009

10.1200/jco.2009.27.15_suppl.lba8002

Cited by 193

Abstract

LBA8002 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Related Papers

No related papers found

Powered by citation graph analysis